Summary Statement: ADARC Program Project on HIV/SIV Vaccine Development

Alan Schultz, Ph.D.
[phone]
as29cani h. gov
Review Group:

SUMMARY STATEMENT PAGE
(Privileged Communication)
Application Number: 1 P01 A143042-01

26

ZAI1 VSG-A (J1)
NIAID SPECIAL EMPHASIS PANEL

AIDS

Meeting Dates:

IRG: OCT/NOV 1997

COUNCIL: JAN/FEB 1998 A24
Requested Start Date: 01/01/1998
PAR97-056

HO, DAVID D, MD
AARON DIAMOND AIDS RESEARCH CTR
455 FIRST AVENUE
NEW YORK, N Y 10016

Project TitleIRG Action:
Human Subjects:
Animal Subjects:

ADARC PROGRAM PROJECT ON HIV/SIV VACCINE DEVELOPMENT
Priority Score: 330
10-N0 HUMAN SUBJECTS INVOLVED
30-ANMLS INV.-VERIFIED, NO IRG CONCERNS OR COMMENT
GENDER, MINORITY, & CLINICAL TRIAL CODES NOT ASSIGNED

PROJECT
YEAR
01
02
03
04
05
TOTAL

DIRECT COSTS
REQUESTED
922,020
1,073,450
1,415,204
1,316,845
1,345,684
6,073,203

DIRECT COSTS
RECOMMENDED
922,020
1,073,450
1,415,204
1,316,845
1,345,684
6,073,203

ESTIMATED
TOTAL COST
1,296,767
1,509,745
1,990,402
1,852,066
1,892,626
8,541,606

NOTE TO APPLICANT FOLLOWS SUMMARY STATEMENT.
BUDGET NOTE: The recommended budget figures shown above have NOT been
recalculated and thus do not reflect the detailed budget recommendations
summarized in the narrative below. In the event an award can be made, an
appropriate budget will be negotiated taking into account the IRG
recommendations.
BIOHAZARD COMMENT: none
ADMINISTRATIVE NOTES: Budget: Project 1; Project 2; Project 3.
Primate Core C{
OUTSIDE OPINION OBTAINED: none
RESUME: This P01 application was submitted in response to PA AI-97-056
"Preclinical/Clinical AIDS Vaccine Development" by a group of investigators
from the Aaron Diamond AIDS Research Center (ADARC) <in New York City. The
major objective of the application, which comprised of three research projects
Continued
Date Released: 01/12/1998 Date Printed: 01/14/1998

=9.
CO.
'.rj.
P